-
EP2593090
European procedure
Extract from the Register of European Patents
EP About this file: EP2593090
| EP2593090 - C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 10.09.2021 Database last updated on 31.08.2024 | |
| Former | Grant of patent is intended Status updated on 21.01.2021 | ||
| Former | Examination is in progress Status updated on 02.12.2020 | ||
| Former | Grant of patent is intended Status updated on 21.04.2020 | ||
| Former | Examination is in progress Status updated on 24.03.2017 | Most recent event Tooltip | 01.06.2024 | New entry: Date of receipt of statement of grounds of an appeal | Applicant(s) | For all designated states Exelixis, Inc. 1851 Harbor Bay Parkway Alameda, CA 94502 / US | [2021/41] |
| Former [2013/21] | For all designated states Exelixis, Inc. 210 East Grand Avenue South San Francisco, CA 94080 / US | Inventor(s) | 01 /
WILSON, Jo Ann 74 Seward Street San Francisco CA 94114 / US | [2013/21] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [N/P] |
| Former [2021/41] | Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB | ||
| Former [2013/21] | Duckett, Anthony Joseph, et al Mathys & Squire LLP 120 Holborn London EC1N 2SQ / GB | Application number, filing date | 11740764.3 | 18.07.2011 | [2021/41] | WO2011US44378 | Priority number, date | US20100365253P | 16.07.2010 Original published format: US 365253 P | US20100370843P | 05.08.2010 Original published format: US 370843 P | [2013/21] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012009722 | Date: | 19.01.2012 | Language: | EN | [2012/03] | Type: | A1 Application with search report | No.: | EP2593090 | Date: | 22.05.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.01.2012 takes the place of the publication of the European patent application. | [2013/21] | Type: | B1 Patent specification | No.: | EP2593090 | Date: | 13.10.2021 | Language: | EN | [2021/41] | Search report(s) | International search report - published on: | EP | 19.01.2012 | Classification | IPC: | A61K9/20, A61K9/28, A61K31/47 | [2020/13] | CPC: |
A61K31/47 (EP,CN,KR,US);
A61K31/00 (KR);
A61K31/33 (KR);
A61K31/395 (KR);
A61K31/435 (KR);
A61K45/06 (US);
A61K9/00 (KR);
A61K9/2004 (KR);
A61K9/2009 (US);
A61K9/2013 (KR,US);
A61K9/2018 (EP,US);
A61K9/2054 (EP,CN,US);
A61K9/2095 (US);
A61K9/28 (US);
A61K9/2833 (US);
|
| Former IPC [2013/21] | A61K9/20, A61K31/47 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/21] | Extension states | BA | 23.01.2013 | ME | 23.01.2013 | Title | German: | PHARMAZEUTISCHE C-MET-MODULATOR-ZUSAMMENSETZUNGEN | [2013/21] | English: | C-MET MODULATOR PHARMACEUTICAL COMPOSITIONS | [2013/21] | French: | COMPOSITIONS PHARMACEUTIQUES MODULATRICES DE C-MET | [2013/21] | Entry into regional phase | 23.01.2013 | National basic fee paid | 23.01.2013 | Designation fee(s) paid | 23.01.2013 | Examination fee paid | Examination procedure | 23.01.2013 | Examination requested [2013/21] | 16.09.2013 | Amendment by applicant (claims and/or description) | 27.03.2017 | Despatch of a communication from the examining division (Time limit: M06) | 12.01.2018 | Reply to a communication from the examining division | 28.01.2019 | Despatch of a communication from the examining division (Time limit: M06) | 08.11.2019 | Reply to a communication from the examining division | 22.04.2020 | Communication of intention to grant the patent | 01.12.2020 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 22.01.2021 | Communication of intention to grant the patent | 23.06.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time | 03.09.2021 | Fee for grant paid | 03.09.2021 | Fee for publishing/printing paid | 03.09.2021 | Receipt of the translation of the claim(s) | Divisional application(s) | EP21202135.6 / EP4014971 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 27.03.2017 | Opposition(s) | Opponent(s) | 01
12.07.2022
14.07.2022
ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE | 02
12.07.2022
14.07.2022
ADMISSIBLE Teva Pharmaceutical Industries Ltd 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | 03
13.07.2022
15.07.2022
ADMISSIBLE Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE | [N/P] |
| Former [2022/34] | |||
| Opponent(s) | 01
12.07.2022
14.07.2022
ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE | ||
| 02
12.07.2022
14.07.2022
ADMISSIBLE Teva Pharmaceutical Industries Ltd 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB | |||
| 03
13.07.2022
15.07.2022
ADMISSIBLE Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE | |||
| Former [2022/33] | |||
| Opponent(s) | 01
12.07.2022
14.07.2022
ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE | ||
| 02
12.07.2022
14.07.2022
ADMISSIBLE Teva Pharmaceutical Industries Ltd 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative D Young & Co LLP 120 Holborn London EC1N 2DY / GB | |||
| 03
13.07.2022
Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Hertfordshire AL10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE | deleted | Deletion: Legal effect of rejection of opposition [ N /P ] | 26.07.2022 | Invitation to proprietor to file observations on the notice of opposition | 06.02.2023 | Reply of patent proprietor to notice(s) of opposition | 18.01.2024 | Date of oral proceedings | 01.02.2024 | Despatch of minutes of oral proceedings | 01.02.2024 | Date of despatch of rejection of opposition | Appeal following opposition | 28.03.2024 | Appeal received No. T0432/24 | 28.03.2024 | Payment of appeal fee | 31.05.2024 | Statement of grounds filed | 20.03.2024 | Appeal received No. T0432/24 | 20.03.2024 | Payment of appeal fee | 29.05.2024 | Statement of grounds filed | 27.03.2024 | Appeal received No. T0432/24 | 27.03.2024 | Payment of appeal fee | 28.05.2024 | Statement of grounds filed | Request for further processing for: | The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent | 03.09.2021 | Request for further processing filed | 03.09.2021 | Full payment received (date of receipt of payment) Request granted | 14.09.2021 | Decision despatched | The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent | 01.12.2020 | Request for further processing filed | 01.12.2020 | Full payment received (date of receipt of payment) Request granted | 14.12.2020 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 08.11.2019 | Request for further processing filed | 08.11.2019 | Full payment received (date of receipt of payment) Request granted | 20.11.2019 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 12.01.2018 | Request for further processing filed | 12.01.2018 | Full payment received (date of receipt of payment) Request granted | 26.01.2018 | Decision despatched | Fees paid | Renewal fee | 10.07.2013 | Renewal fee patent year 03 | 14.07.2014 | Renewal fee patent year 04 | 10.07.2015 | Renewal fee patent year 05 | 25.07.2016 | Renewal fee patent year 06 | 12.07.2017 | Renewal fee patent year 07 | 11.07.2018 | Renewal fee patent year 08 | 15.07.2019 | Renewal fee patent year 09 | 14.07.2020 | Renewal fee patent year 10 | 15.07.2021 | Renewal fee patent year 11 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 13.10.2021 | CY | 13.10.2021 | EE | 13.10.2021 | HR | 13.10.2021 | MC | 13.10.2021 | MK | 13.10.2021 | RS | 13.10.2021 | SI | 13.10.2021 | SM | 13.10.2021 | BG | 13.01.2022 | IS | 13.02.2022 | [2024/22] |
| Former [2024/20] | AL | 13.10.2021 | |
| CY | 13.10.2021 | ||
| EE | 13.10.2021 | ||
| HR | 13.10.2021 | ||
| MC | 13.10.2021 | ||
| RS | 13.10.2021 | ||
| SI | 13.10.2021 | ||
| SM | 13.10.2021 | ||
| BG | 13.01.2022 | ||
| IS | 13.02.2022 | ||
| Former [2023/11] | AL | 13.10.2021 | |
| EE | 13.10.2021 | ||
| HR | 13.10.2021 | ||
| MC | 13.10.2021 | ||
| RS | 13.10.2021 | ||
| SI | 13.10.2021 | ||
| SM | 13.10.2021 | ||
| BG | 13.01.2022 | ||
| IS | 13.02.2022 | ||
| Former [2023/01] | AL | 13.10.2021 | |
| EE | 13.10.2021 | ||
| HR | 13.10.2021 | ||
| RS | 13.10.2021 | ||
| SI | 13.10.2021 | ||
| SM | 13.10.2021 | ||
| BG | 13.01.2022 | ||
| IS | 13.02.2022 | ||
| Former [2022/49] | AL | 13.10.2021 | |
| EE | 13.10.2021 | ||
| HR | 13.10.2021 | ||
| RS | 13.10.2021 | ||
| SM | 13.10.2021 | ||
| BG | 13.01.2022 | ||
| IS | 13.02.2022 | ||
| Former [2022/34] | EE | 13.10.2021 | |
| HR | 13.10.2021 | ||
| RS | 13.10.2021 | ||
| SM | 13.10.2021 | ||
| BG | 13.01.2022 | ||
| IS | 13.02.2022 | ||
| Former [2022/33] | HR | 13.10.2021 | |
| RS | 13.10.2021 | ||
| SM | 13.10.2021 | ||
| BG | 13.01.2022 | ||
| IS | 13.02.2022 | ||
| Former [2022/24] | HR | 13.10.2021 | |
| RS | 13.10.2021 | ||
| BG | 13.01.2022 | ||
| IS | 13.02.2022 | ||
| Former [2022/21] | RS | 13.10.2021 | |
| BG | 13.01.2022 | ||
| Former [2022/19] | BG | 13.01.2022 | Cited in | International search | [ID]WO2005030140 (EXELIXIS INC [US], et al) [ID] 1-30 * table 2, compound 12 * * example 48 * * table 4, entry 289 * * paragraphs [0025] , [0031] , [0252] , [0253] *; | [IDP]WO2010083414 (EXELIXIS INC [US], et al) [IDP] 1-30* the whole document *; | [I] - KURZROCK R ET AL, "379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC)", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 6, no. 12, doi:10.1016/S1359-6349(08)72313-9, ISSN 1359-6349, (20081001), page 119, (20081001), XP025534443 [I] 1-30 * the whole document * DOI: http://dx.doi.org/10.1016/S1359-6349(08)72313-9 | by applicant | WO2005030140 | WO2008083319 | WO2010083414 | - PLOWMAN ET AL., DN&P, (1994), vol. 7, no. 6, pages 334 - 339 | - MAULIK ET AL., CYTOKINE & GROWTH FACTOR REVIEWS, (2002), vol. 13, pages 41 - 59 | - LONGATI ET AL., CURR DRUG TARGETS, (2001), vol. 2, pages 41 - 55 | - FUNAKOSHI ET AL., CLINICA CHIMICA ACTA, (2003), pages 1 - 23 | - MATTER A., DRUG DISC. TECHNOL., (2001), vol. 6, pages 1005 - 1024 | - REILLY, LEUK. LYMPHOMA, (2003), vol. 44, pages 1 - 7 | - GOODMAN, GILMAN'S, The Pharmacological Basis of Therapeutics, MCGRAW-HILL PRESS, (2001), pages 155 - 173 | - J.W. MULLIN, J. NYVLT, Programmed Cooling Batch Crystallizers, CHEMICAL ENGINEERING SCIENCE, (1971), vol. 26, page 3690377 | - A.E. BENNETT ET AL., J. CHEM. PHYS., (1995), vol. 103, page 6951 | - G. METZ, X. WU, S.O. SMITH, J. MAGN. RESON. A, (1994), vol. 110, pages 219 - 227 | - W.L. EARL, D.L VANDERHART, J. MAGN. RESON., (1982), vol. 48, pages 35 - 54 | Opposition | WO2005030140 | WO2010083414 | WO2012009722 | - KURZROCK et al., "379 POSTER A phase I study of XL184, a MET, VEGFR2, and RET kinase inhibitor, administered orally to patients (pts) with advanced malignancies, including a subgroup of pts with medullary thyroid cancer (MTC", EUROPEAN JOURNAL OF CANCER, OXFORD, GB, vol. 6, no. 12, doi:10.1016/S1359-6349(08)72313-9, XP025534443 DOI: http://dx.doi.org/10.1016/S1359-6349(08)72313-9 | - "Die Tablette (auszug)", Ritschel Wolfgang A., Bauer-Brandl Annette, Die Tablette, 2. Auflage, (20020101), pages 67 - 77, 85 - 97, 115 - 130, 143 - 160, XP055947010 | - Stahl P. Heinrich, Wermuth Camille G., Handbook of Pharmaceutical Salts - Properties, Selection and Use, (20080101), pages 292 - 293, XP055947023 | - Fiedler Lexikon der Hilfsstoffe für Pharamazie, Kosmetik und angrenzende Gebiete, 5. auflage, (2002), vol. 9, page 1248, XP055281404 | - "History of Changes for Study: NCT00596648", (20110602), URL: https://clinicaltrials.gov/ct2/history/NCT00596648?V_16=View#StudyPageTop, XP055947033 | - Rowe Raymond C, Sheskey Paul J, Quinn Marian E, Handbook of Pharmaceutical Excipients, 6th ed., (20090101), pages 129 - 133, 185 - 188, 206 - 208, 317 - 322, 359 - 361, 404 - 407, XP055947144 | - "Chapter 13 - Tablet Dosage Forms", Alexander T. Florence, Siepmann Juergen, Modern Pharmaceutics, 5th edition, (20090101), vol. 1 - Basic Principles and Systems, pages 481 - 497, XP055752956 | - "Tablet Formulation", James Swarbrick, Encyclopedia of Pharmaceutical Technology, Third Edition, (20070101), vol. 1, pages 3641 - 3672, XP055752951 | - ANSELL ET AL., PHARMACEUTICAL DOSAGE FORMS AND DRUG DELIVERY SYSTEMS, (19990000), pages 209 - 210, XP003033294 | - Göran Alderborn, "27. Tablets and compaction", Göran Alderborn, M.E. Aulton, Pharmaceutics: The Science of Dosage Form Design, 2nd edition, (20020101), pages 397 - 412, XP055282904 | - "Guidance for Industry Q1A(R2) Stability Testing of New Drug Substances and Products", (20031101), pages 1 - 22, URL: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073369.pdf, XP055289845 | - JAMES WELLS, "8. PHARMACEUTICAL PREFORMULATION: THE PHYSICOCHEMICAL PROPERTIES OF DRUG SUBSTANCES.", JAMES WELLS, AULTON M.E., PHARMACEUTICS. THE SCIENCE OF DOSAGE FORM DESIGN, 2nd ED., (20020101), pages 113 - 138, ISBN 978-0-443-05517-1, XP003035880 | - Arko, L. ; Katsyv, I. ; Park, G.E. ; Luan, W.P. ; Park, J.K., "Experimental approaches for the treatment of malignant gliomas", Pharmacology & Therapeutics, ELSEVIER., GB, GB , (20101001), vol. 128, no. 1, ISSN 0163-7258, pages 1 - 36, XP027278601 | - L. Mologni, "Development of RET Kinase Inhibitors for Targeted Cancer Therapy", Current medicinal chemistry, Bentham, NL, NL , (20110101), vol. 18, no. 2, doi:10.2174/092986711794088308, ISSN 0929-8673, pages 162 - 175, XP055238903 DOI: http://dx.doi.org/10.2174/092986711794088308 | - M. J. Willhauck, M. Schott, M. C. Kreiss , M. Fassnacht, C. Spitzweg, "Neue Therapieoptionen bei fortgeschrittenen Schilddrüsenkarzinomen. New therapeutic options for advanced thyroid cancer", Deutsche Medizinische Wochenschrift, (20110000), vol. 136, no. 22, pages 1165 - 1168, XP055946985 DOI: http://dx.doi.org/10.1055/s-0031-1280531 | - Zhang Ying, Et Al, "XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC", IDrugs, (20100201), vol. 13, no. 2, pages 112 - 121, XP055923006 | - R. Kurzrock, S. I. Sherman, D. W. Ball, A. A. Forastiere, R. B. Cohen, R. Mehra, D. G. Pfister, E. E. W. Cohen, L. Janisch, F. Nauling, D. S. Hong, C. S. Ng, L. Ye, R. F. Gagel, J. Frye, T. Muller, M. J. Ratain, R. Salgia, "Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer", Journal of Clinical Oncology, (20110701), vol. 29, no. 19, doi:10.1200/JCO.2010.32.4145, ISSN 0732183X, pages 2660 - 2666, XP055194951 DOI: http://dx.doi.org/10.1200/JCO.2010.32.4145 | - Anonymous, "History of Changes for Study: NCT00704730. Efficacy Study of XL184 in Adults With Medullary Thyroid Cancer", ClinicalTrials.gov NCT00704730, (20100528), ClinicalTrials.gov NCT00704730, URL: https://clinicaltrials.gov/ct2/history/NCT00704730?V_57=View#StudyPageTop, (20220728), XP055947016 | - Anonymous, "History of Changes for Study: NCT00704288. Study of XL184 in Adults With Glioblastoma Multiforme ", ClinicalTrials.gov NCT00704288, (20100407), ClinicalTrials.gov NCT00704288, URL: https://clinicaltrials.gov/ct2/history/NCT00704288?V_10=View#StudyPageTop, (20220728), XP055947019 | - Rowe R. C., Et Al, "Cellulose. Lactose, anhydrous. Magnesium stearate", Handbook of Pharmaceutical Excipients. 5th ed., PhP , (20060101), page 132-135, 188, 211, 336, 385-388, 430, XP055947049 | - Comp, "EMEA/666785/2008 Corr. 2", EMEA, (20081222), pages 1 - 10, EMEA, (20220728), XP055947026 | - Ritschel W., A. Bauer-Brandl, "Kapitel 2", Die Tablette - Handbuch der Entwicklung, Herstellung und Qualitatssicherung, Editio Cantor Verlag, (20020101), pages 67 - 80, XP055947012 | - Kurt H. Bauer; Karl-Heinz Frömming; Claus Führer, "22.3 Ursachen von Instabilitäten", Kurt H. Bauer; Karl-Heinz Frömming; Claus Führer, Bauer K.H., Frömming K-H., Führer C., Pharmazeutische Technologie, Germany , Gustav Fischer Verlag , (19970101), pages 437 - 439, ISBN 3-437-25630-0, XP009552856 | - Wolfgang A. Ritschel ; Annette Bauer-Brandl, "6.6 Prüfung des Feuchtigkeitsgehaltes // 6.7 Prüfung des pH-Wertes", Wolfgang A. Ritschel ; Annette Bauer-Brandl, Wolfgang A. Ritschel ; Annette Bauer-Brandl, Die Tablette : Handbuch der Entwicklung, Herstellung und Qualitätssicherung, Aulendorf, DE, ECV - Editio-Cantor-Verl., (20020101), pages 523 - 523, ISBN 3-87193-228-0, XP009552857 | - ECV - Editio-Cantor-Verl., "4.8.11 Feuchtigkeitsgehalt", ECV - Editio-Cantor-Verl., Wolfgang A. Ritschel ; Annette Bauer-Brandl, Die Tablette : Handbuch der Entwicklung, Herstellung und Qualitätssicherung, Aulendorf, DE, ECV - Editio-Cantor-Verl., (20020101), pages 364 - 367, ISBN 3-87193-228-0, XP009552858 |